Comparable stake leader
Pilo Shlomo
SEC ownership of Raphael Pharmaceutical Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001415397.
Disclosed value leader
Pilo Shlomo
Comparable rows
0/6
Latest evidence
20 Nov 2025
- Public ticker
- RAPH on OTC
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Pilo Shlomo
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
20 Nov 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001415397
- Issuer location
- Las Vegas, NV
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Raphael Pharmaceutical Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Pilo Shlomo
Disclosed value leader
Pilo Shlomo
Comparable rows
0/6
Latest evidence
20 Nov 2025
3/4/5
Highest disclosed value: $1,991,851
6 rows are not safely comparable across share classes.
Quick read
Pilo Shlomo has the largest disclosed position value at $1.99M.
0 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Pilo Shlomo's linked filing trail.
Disclosed position value
Top 5
Pilo Shlomo
$1.99M
Guy Ofir
$633.2K
Hayon Igal Louria
$499.5K
Ajay Kumar Dhadha
$377.4K
Yehuda Eliya
$176K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 6 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Pilo Shlomo |
3/4/5
Chief Executive Officer, Director, 10%+ Owner
|
—
mixed-class rows
|
$1,991,851
5,083,701 shares
mixed-class rows
|
— | 02 Mar 2025 |
| Guy Ofir |
3/4/5
Chief Financial Officer, Director
|
—
mixed-class rows
|
$633,228
2,266,455 shares
mixed-class rows
|
— | 26 Jul 2022 |
| Hayon Igal Louria |
3/4/5
Chief Technology Officer
|
—
class O/S missing
|
$499,500
1,349,000 shares
|
— | 20 Nov 2025 |
| Ajay Kumar Dhadha |
3/4/5
Director
|
—
mixed-class rows
|
$377,411
1,004,820 shares
mixed-class rows
|
— | 05 Mar 2025 |
| Yehuda Eliya |
3/4/5
Director
|
—
class O/S missing
|
$176,000
352,000 shares
|
— | 25 Nov 2023 |
| Joseph Press |
3/4/5
Director
|
—
mixed-class rows
|
$140,000
385,000 shares
mixed-class rows
|
— | 26 Jul 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 23 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-7 of 7 reporting-owner rows connected to Raphael Pharmaceutical Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
7
Largest Forms 3/4/5 holder
Pilo Shlomo
Net 12M change
$0
Latest report
20 Nov 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Pilo Shlomo | Chief Executive Officer, Director, 10%+ Owner | $1,991,851 | Mixed | 02 Mar 2025 | ||
| Guy Ofir | Chief Financial Officer, Director | $633,228 | Mixed | 26 Jul 2022 | ||
| Hayon Igal Louria | Chief Technology Officer | $499,500 | Mixed | 20 Nov 2025 | ||
| Ajay Kumar Dhadha | Director | $377,411 | Mixed | 05 Mar 2025 | ||
| Yehuda Eliya | Director | $176,000 | Mixed | 25 Nov 2023 | ||
| Joseph Press | Director | $140,000 | Mixed | 26 Jul 2022 | ||
| Zvi Laufer Laor | Director | Mixed | 01 Aug 2025 |
Recent insider transactions for Raphael Pharmaceutical Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Hayon Igal Louria | RAPH | Common Stock | Exercise of in-the-money or at-the-money derivative security | 35% | 350,000 | 1,349,000 | 20 Nov 2025 | Direct | ||
| Hayon Igal Louria | RAPH | Warrants to purchase Common Stock | Exercise of in-the-money or at-the-money derivative security | -100% | -350,000 | 0 | 20 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.